Venous thromboembolism (VTE) represents a major clinical and social problem. In the general population it is estimated that the yearly incidence of Deep Venous Thrombosis (DVT) is of 69 cases out of 100,000 subjects. This incidence increases significantly in the population with cancer (1390 cases out of 100,000 subjects); in patients with cancer, DVT is the second cause of death.
In Italy, around 100 thousand patients are affected every year by acute syndrome coronary (ACS), term used to describe a variety of clinical conditions that include acute myocardial infarction and unstable angina: ACS is one of the most frequent reason of hospital admissions in the western world.
The activity of Italfarmaco in the prophylaxis and treatment of Venous Thromboembolism is consolidated by a long experience started with Calciparina, (unfractioned heparin (UFH)), and has its natural evolution in Nadroparin Calcium, (low molecular weight heparin (LMWH)), more flexible and with a comparable safety with UFH marketed by Italfarmaco with the brands Seleparina, Fraxiparina, Seledie e Fraxodi.
Since the beginning of 2019, Italfarmaco has strengthened its presence in this therapeutic area by introducing the first biosimilar of low molecular weight heparins, Enoxaparin Sodium, fully developed and produced in Italy, marketed under the trade names of Ghemaxan.